CareLit Fachartikel
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells
TTH Wissniowski, D Strobel, EG Hahn, R Voll, M Ocker · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Dokument
1138986
CareLit-ID
Jahr
2010
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Aims: The prognosis of pancreatic cancer remains disappointing due to a high intrinsic resistance against chemotherapeutic agents. Standard gemcitabine therapies have improved overall survival only marginally and recently, inhibition of the proteasome by the boronic acid derivative bortezomib has been introduced as a novel therapeutic strategy for solid and hematologic malignancies including pancreatic cancer. Methods: The mucus-producing pancreatic cancer cell line Capan-1 was cultured under standard conditions and treated with different concentrations of gemcitabine or bortezomib. Mucus production was suppress…
Schlagworte
Bortezomib
Apoptosis
After
Caspase 12
Caspase 3
Tumor
Zeitschrift für Gastroenterologie
